Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Andy Purnomo, Ugroseno Yudho Bintoro, Made Putra Sedana, Ami Ashariati

Abstract


Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent of Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis.

Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed using Fisher exact test which was considered significant if p<0.05.

Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin was 9.1 g/dL, median leukocyte was 180x109 /L, median thrombocyte was 645x109 /L, median eosinophil was 2.9%, median basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.

Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic response with imatinib.

Keywords: Hasford score, hematologic response, CML, imatinib


Full Text:

PDF

References


Jabbour E, Cortes JE, Giles FJ, O' Brien S, Kantarijan HM. Current and emerging treatment option in chronic myeloid leukemia. Cancer. 2007; 109(11): 2171-81, CrossRef.

Ugroseno YB. Chronic Myelogenous Leukemia Patogenesis, Diagnosis dan Terapi [Dissertation]. Surabaya: Universitas Airlangga: 2014, article.

Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia . Best Pract Res Clin Haematol. 2009; 22(3): 295-302, CrossRef.

Deininger MW. Chronic myeloid leukemia. In: Greer JP, Arber DA, Glader B, List AF, Means RT Jr, Paraskevas F, et al, editors. Wintrobe's Clinical Hematology. 13th ed. Philadelphia: Wolters Kluwer Health Lippincott Williams & Wilkins; 2014. p.1705-19, article.

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90(11): 850-8, CrossRef.

Valent P, Horny HP. The underestimated role of basophils in Ph+ chronic myeloid leukaemia. Eur J Clin Invest. 2018; 48 (10): e13000, CrossRef.

Sinha SK, Sinha S, Mandal PK, Bhattacharyya NK, Pandey A, Gupta P. A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers . Indian J Pathol Microbiol. 2013; 56(3): 216-20, CrossRef.

Dybko J, Jaźwiec B, Haus O, Urbaniak-Kujda D, Kapelko-Słowik K, Wróbel T, et al. The Hasford score may predict molecular response in chronic myeloid leukemia patients: a single institution experience. Dis Markers. 2016; 2016: 7531472, CrossRef.

Marin D, Bazeos A, Mahon FX. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14): 2381-8, CrossRef.

Reksodiputro AH. Clinical characteristic and hematologic response to imatinib in patients with chronic phase myeloid leukemia at Cipto Mangunkusumo Hospital. Acta Med Indones. 2010; 42(1): 2-5, article.

Instituti i Shëndetit Publik [Internet]. Roko D, Babameto-Laku A, Mokini V, Cikuli M: Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients [updated 2013 Oct 9; cited 2018 Dec 31]. Available from: http://www.ishp.gov.al/.

Ashariati A, Ugroseno YB. Profile of BCR ABL transcript level based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib. Acta Med Indones. 2013: 45(2): 107-13, article.

Sawyers CL. Imatinib induces hematologic and cytogenetic responses in patientswith chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99(10): 3530-9, CrossRef.

Kantarijan HM, Cortes J. Chronic myeloid leukemia. In: Dennis LK, Stephen LH, Dahn LL editors. Harrison Hematology and Oncology. 3rd ed.New York: Mc Graw Hill; 2017. p.181.

Liesveld JL, Licthman MA. Chronic myelogenous leukemia an related disorders. In: Kaushanky K, Licthman MA, editors. William Manual of Hematology. 9th ed. New York: Mc Graw hill; 2016. p.1437.

Bilen Y, Erdem F. Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia:a single-center experience in Turkey. Turk J Med Sci. 2012; 42(1): 31-8, article.

Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India. 2007; 55: 103-7, article.

Elbedewy TA. The utility and applicability of chronic myeloid leukemia scoring systems for predicting the prognosis of Egyptian patients on Imatinib: retrospective study. J Leuk 2016; 4: 210, CrossRef.

Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. Onco Targets Ther. 2015; 8: 2485-92, CrossRef.

Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014; 105(1): 105-9, CrossRef.

Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Dasappa L, Jacob LA, Mallekavu SB, et al. Prognostic and predictive implications of Sokal, Euro and Eutos scores in chronic myeloid leukaemia in the imatinib era-experience from tertiary oncology centre in Southern India. Ecancermedicalscience. 2016;10: 679, CrossRef.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009; 113(15): 3428-34, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v3i2.56

Copyright (c)

Indexed by:

                     

                    

                    


Cell and BioPharmaceutical Institute